Presidential Proclamation — National Diabetes Month, 2013

I encourage all Americans to talk to their health care provider about steps they can take to prevent or manage this disease. With diabetes ranking among the leading causes of death in the United States, my Administration is committed to supporting Americans living with diabetes, investing in promising scientific research, advancing work toward improved treatment and care, and bolstering prevention efforts. Thanks to the Affordable Care Act, beginning in 2014, no American with diabetes can be denied health insurance based on their diagnosis, and in most plans, Americans at increased risk can access diabetes screenings at no cost to them. The National Diabetes Prevention Program engages private and public partners to help people with prediabetes adopt lifestyles that can prevent or delay Type 2 diabetes, and the National Diabetes Education Program focuses on delaying and preventing disease onset while also working to improve outcomes for those living with the disease.
For the original version including any supplementary images or video, visit http://www.whitehouse.gov/the-press-office/2013/10/31/presidential-proclamation-national-diabetes-month-2013

Salix to Buy Santarus for $2.6 Billion for Diabetes Drug

The combined company will have revenue of $1.3 billion and benefit from merging two sales forces and increasing its slate of experimental drugs, Salix Chief Executive Officer Carolyn Logan said in the statement. Salixs top-selling drug is Xifaxan, for travelers diarrhea, which drew $514.5 million in 2012 sales . Santarus sells Glumetza for Type 2 diabetes , which analysts estimate will generate $221.6 million in 2015 revenue, and Zegerid for heartburn, forecast for $106.3 million in sales. The deal is transformative for Salix both commercially and financially, fulfilling many of our strategic needs while providing immediate and significant accretion in 2014 and beyond, Logan said in the statement released yesterday. The companies said they expect the acquisition to close in the first quarter of 2014.
For the original version including any supplementary images or video, visit http://www.bloomberg.com/news/2013-11-07/salix-to-buy-santarus-for-2-6-billion-for-diabetes-drug.html